Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...

In early 2024, the expansion of Flamingo-01 into 5 EU countries was approved by European regulators. Since that time, 77 clinical trial sites have been activated, and study recruitment is well ...

Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

A Plymouth woman has been raising funds for Cancer Research whilst dressed as a pink flamingo. Derriford Hospital maternity support worker, Sally Anne Symons, has been walking 10,000 steps a day since ...

About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients ...

(Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

provided an update on its Phase III clinical trial, FLAMINGO-01, which is investigating the immunotherapy GLSI-100 for preventing breast cancer recurrences. The Data Safety Monitoring Board (DSMB ...

The networks hold annual scientific meetings where Flamingo-01 has been introduced and where the Company has presented in the past. GEICAM is the leading group in breast cancer research in Spain ...